CA2244094A1 - Use of colostrum for the treatment of constipation - Google Patents
Use of colostrum for the treatment of constipation Download PDFInfo
- Publication number
- CA2244094A1 CA2244094A1 CA 2244094 CA2244094A CA2244094A1 CA 2244094 A1 CA2244094 A1 CA 2244094A1 CA 2244094 CA2244094 CA 2244094 CA 2244094 A CA2244094 A CA 2244094A CA 2244094 A1 CA2244094 A1 CA 2244094A1
- Authority
- CA
- Canada
- Prior art keywords
- colostrum
- constipation
- treatment
- gastro
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Gastro-resistant pharmaceutical formulations containing animal colostrum for the treatment of constipation, and the use of colostrum for the treatment of constipation.
Description
Use of colostrum for the treatment of constipation The present invention relates to sastro-resistant pharmaceutical formulations containing Ani~al colostrum for the treatment of constipation, and the use of colostrum for the treatment of constipation.
Constipation is a widespread problem in adultfi and children, consisting in the difficult or infrequent passage of the stool mass through the colon, which mass accumulates becoming hard following water reasdorption.
Constipation can be acute or chronic, due to organic, traumatic, functional, neurogenic conditions and the like.
The treatment of constipation involves various alternatives:
- ~nrichment in the vegetable fibres content of the diet, use of agents increasing stool bulk (natural or semisynthetic polysaccharides and cellulose derivatives, such as bran, psyllium and methylcellulose) or mineral oils, to increase stool bulk and keep it softer, th~nks to an increased ~ adsorption of liquids in the intestinal tract. Such an approach, however, is not always sufficient to overcome the problem.
- Use of saline or osmotic laxatives, such as salts (magnesium; sodium and potassium sulfates, phosphates and tartrates); lactulose, sorbitol:
they transit rapidly in the bowel, where they cause an increase in osmotic pressure and therefore an CONFIRM~ION t:OPl' increase in water adsorption in the feces and the peristalsis stimulation.
This laxatives act rapidly and are generally used to empty the bowel prior to diagnostic procedures and surgery; they are contraindicated in case of renal failure and heart failure.
- Use of stimulant laxatives (phenolphthalein, castor oil, anthraquinone derivatives such as senna and cascara), which promote an increase in peristalsis and intraluminal fluid. They can cause a remar~able irritation of bowel and electrolyte ~alance disturbances.
Therefore, a medicament promoting elimination without causing the above mentioned side-effects is much needed.
The present invention aims at overcoming the above cited problems, by the use of gastro-resistant pharmaceutical formulations containing equine, bovine or anyhow An~mAl, but preferably equine, colostrum, for the treatment of constipation.
The present invention further relates to the use of equine, bovine or anyhow animal, but preferably equine, colostrum, as a laxative.
~ It has surprisingly been found that colostrum, administered to patients suffering from constipation, acts favourably inducing elimination of stool mass without causing irritation, cramps or electrolyte disturbances. ;, In fact, during the clinic trials, 11 out of 12 3~ treated patients showed a favourable response to the treatment with colostrum, obtaining an effective, natural laxative action.
It should be stressed that colostrum exerts and effective action in the treatment of women suffering from pregnancy or post-partum constipation, which are delicate conditions difficult to treat, as the response to the treatment with ~oth bulking agents and common laxatives is poor, and contraindications to pharmacological treatment are remarkable, since drugs can induce uterus contractions in the pregnant woman (as is the case with castor oil~ or they can be present in breast milk in amounts adversely affecting the breast-fed infant (particularly anthraquinone laxatives). The colostrum treated patients obtained an effective, physiological laxative effect without any side-effects.
The gastro-resistant pharmaceutical formulations of invention contain powder or liquid colostrum in amounts of 10 mg to 5 g per unitary dose.
More particularly, the formulations of the invention comprise gastro-resistant tablets containing 2~ powdered, freeze-dried or sprayzed colostrum, or gastro-resistant pearls containing liquid colostrum.
The gastro-resistant tablets or pearls of invention are prepared according to the conventional pharmaceutical techniques for the preparation of gastro-resistant formulations, for example an enteric coatingcan be applied to a colostrum core by means of fluidized bed coating or pan coating techniques.
The enteric coating is used to protect colostrum against the gastric acid environment, such a coating can consist of copolymerized methacrylic acid/methacrylic acid methyl esters, such as those known under the names .
EudragitR (commercialized by Rohm Pharma~, polymers such 8s cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, water-based polymer dispersions, ~uch as EudragitR (by Rohm Pharma), AquatericR (FMC Corp.). The enteric coating can optionally contain plasticizers such as triacetin, cetanol, citric and phthalic acids esters.
The formulations of the invention can optionally contain other active ingredients known to have a beneficial effect on the condition to treat, particularly vegetable extracts.
According to a further aspect of the invention, the formulations can contain colostrum mixed with milk.
The following examples further illustrate the invention.
~xample 1 One enteric-coated tablet contains:
Powder colostrum 145 mg Hydroxypropyl methylcellulose phthalate6 mg Cetyl alcohol 0.5 mg The enteric coating solution is applied on the colostrum core by fluidized bed coating.
~xample 2 One-enteric-coated tablet contains:
Powder colostrum 64 mg Powder milk 45 mg ~ydroxypropyl methylcel~ulose phthalate32 mg Cetyl alcohol - 5 mg The enteric coating solution is applied on the colostrum core by fluidized bed coating.
W 097/26899 PCT~EP97/00300 Fxample 3 One 400 mg capsule contains:
Freeze-dried colostrum t2 mg Cassia acutifolia dried leaves 25 mg Aloe vera 40 mg Gelidum e Gracilaria 120 mg Rheum Rhaponticum rhizome 85 mg Carbo ligni 118 mg The whole mass is mixed thoroughly, then placed into a gastro-resistant capsule.
Fxample 4 One 400 mg capsule contains:
Freeze-dried colostrum 6Q mg Cassia acutifolia dried leaves 25 mg Aloe vera 40 mg Gelidum e Gracilaria 105 mg Rheum Rhaponticum rhizome 80 mg Carbo ligni 90 mg The whole mass is mixed thoroughly, then placed into a gastro-resistant capsule.
Constipation is a widespread problem in adultfi and children, consisting in the difficult or infrequent passage of the stool mass through the colon, which mass accumulates becoming hard following water reasdorption.
Constipation can be acute or chronic, due to organic, traumatic, functional, neurogenic conditions and the like.
The treatment of constipation involves various alternatives:
- ~nrichment in the vegetable fibres content of the diet, use of agents increasing stool bulk (natural or semisynthetic polysaccharides and cellulose derivatives, such as bran, psyllium and methylcellulose) or mineral oils, to increase stool bulk and keep it softer, th~nks to an increased ~ adsorption of liquids in the intestinal tract. Such an approach, however, is not always sufficient to overcome the problem.
- Use of saline or osmotic laxatives, such as salts (magnesium; sodium and potassium sulfates, phosphates and tartrates); lactulose, sorbitol:
they transit rapidly in the bowel, where they cause an increase in osmotic pressure and therefore an CONFIRM~ION t:OPl' increase in water adsorption in the feces and the peristalsis stimulation.
This laxatives act rapidly and are generally used to empty the bowel prior to diagnostic procedures and surgery; they are contraindicated in case of renal failure and heart failure.
- Use of stimulant laxatives (phenolphthalein, castor oil, anthraquinone derivatives such as senna and cascara), which promote an increase in peristalsis and intraluminal fluid. They can cause a remar~able irritation of bowel and electrolyte ~alance disturbances.
Therefore, a medicament promoting elimination without causing the above mentioned side-effects is much needed.
The present invention aims at overcoming the above cited problems, by the use of gastro-resistant pharmaceutical formulations containing equine, bovine or anyhow An~mAl, but preferably equine, colostrum, for the treatment of constipation.
The present invention further relates to the use of equine, bovine or anyhow animal, but preferably equine, colostrum, as a laxative.
~ It has surprisingly been found that colostrum, administered to patients suffering from constipation, acts favourably inducing elimination of stool mass without causing irritation, cramps or electrolyte disturbances. ;, In fact, during the clinic trials, 11 out of 12 3~ treated patients showed a favourable response to the treatment with colostrum, obtaining an effective, natural laxative action.
It should be stressed that colostrum exerts and effective action in the treatment of women suffering from pregnancy or post-partum constipation, which are delicate conditions difficult to treat, as the response to the treatment with ~oth bulking agents and common laxatives is poor, and contraindications to pharmacological treatment are remarkable, since drugs can induce uterus contractions in the pregnant woman (as is the case with castor oil~ or they can be present in breast milk in amounts adversely affecting the breast-fed infant (particularly anthraquinone laxatives). The colostrum treated patients obtained an effective, physiological laxative effect without any side-effects.
The gastro-resistant pharmaceutical formulations of invention contain powder or liquid colostrum in amounts of 10 mg to 5 g per unitary dose.
More particularly, the formulations of the invention comprise gastro-resistant tablets containing 2~ powdered, freeze-dried or sprayzed colostrum, or gastro-resistant pearls containing liquid colostrum.
The gastro-resistant tablets or pearls of invention are prepared according to the conventional pharmaceutical techniques for the preparation of gastro-resistant formulations, for example an enteric coatingcan be applied to a colostrum core by means of fluidized bed coating or pan coating techniques.
The enteric coating is used to protect colostrum against the gastric acid environment, such a coating can consist of copolymerized methacrylic acid/methacrylic acid methyl esters, such as those known under the names .
EudragitR (commercialized by Rohm Pharma~, polymers such 8s cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, water-based polymer dispersions, ~uch as EudragitR (by Rohm Pharma), AquatericR (FMC Corp.). The enteric coating can optionally contain plasticizers such as triacetin, cetanol, citric and phthalic acids esters.
The formulations of the invention can optionally contain other active ingredients known to have a beneficial effect on the condition to treat, particularly vegetable extracts.
According to a further aspect of the invention, the formulations can contain colostrum mixed with milk.
The following examples further illustrate the invention.
~xample 1 One enteric-coated tablet contains:
Powder colostrum 145 mg Hydroxypropyl methylcellulose phthalate6 mg Cetyl alcohol 0.5 mg The enteric coating solution is applied on the colostrum core by fluidized bed coating.
~xample 2 One-enteric-coated tablet contains:
Powder colostrum 64 mg Powder milk 45 mg ~ydroxypropyl methylcel~ulose phthalate32 mg Cetyl alcohol - 5 mg The enteric coating solution is applied on the colostrum core by fluidized bed coating.
W 097/26899 PCT~EP97/00300 Fxample 3 One 400 mg capsule contains:
Freeze-dried colostrum t2 mg Cassia acutifolia dried leaves 25 mg Aloe vera 40 mg Gelidum e Gracilaria 120 mg Rheum Rhaponticum rhizome 85 mg Carbo ligni 118 mg The whole mass is mixed thoroughly, then placed into a gastro-resistant capsule.
Fxample 4 One 400 mg capsule contains:
Freeze-dried colostrum 6Q mg Cassia acutifolia dried leaves 25 mg Aloe vera 40 mg Gelidum e Gracilaria 105 mg Rheum Rhaponticum rhizome 80 mg Carbo ligni 90 mg The whole mass is mixed thoroughly, then placed into a gastro-resistant capsule.
Claims (7)
1. Gastro-resistant pharmaceutical formulations containing colostrum for the treatment of constipation.
2. Pharmaceutical formulations according to claim 1, wherein the colostrum is equine, bovine or anyhow animal, but preferably equine, colostrum.
3. Formulations according to claims 1 and 2, in the form of gastro-resistant tablets or pearls, containing respectively powder or liquid colostrum.
4. Formulations according to the above claims, containing 10 mg to 5 g of powder or liquid colostrum per unitary dose.
5. Formulations according to claims 3 and 4, wherein the powder colostrum is freeze-dried or sprayzed.
6. Formulations according to the above claims, further containing powder milk.
7. The use of colostrum for the preparation of a medicament for the treatment of constipation.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT96MI000113A IT1282952B1 (en) | 1996-01-24 | 1996-01-24 | GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF CONSTIPATION |
| ITMI96A000113 | 1996-01-24 | ||
| PCT/EP1997/000300 WO1997026899A1 (en) | 1996-01-24 | 1997-01-23 | Use of colostrum for the treatment of constipation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2244094A1 true CA2244094A1 (en) | 1997-07-31 |
Family
ID=29421795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2244094 Abandoned CA2244094A1 (en) | 1996-01-24 | 1997-01-23 | Use of colostrum for the treatment of constipation |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2244094A1 (en) |
-
1997
- 1997-01-23 CA CA 2244094 patent/CA2244094A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5514663A (en) | Senna dosage form | |
| Akolade et al. | Encapsulation in chitosan-based polyelectrolyte complexes enhances antidiabetic activity of curcumin | |
| US4405596A (en) | Pharmaceutical preparations for and treatment procedures involving increasing plasma bicarbonate level | |
| AU2001244611B2 (en) | Preparations for preventing bile acid diarrhea | |
| WO1995011024A1 (en) | Picosulphate dosage form | |
| EP1017404B1 (en) | Pharmaceutical composition for the treatment of inflammatory bowel disease | |
| CN105163743A (en) | Pharmaceutical compositions for the treatment of helicobacter pylori | |
| EP0495105A1 (en) | Inhibitor of absorption of digestion product of food and drink | |
| RU2207866C2 (en) | Application of phospholipid complex extracts from vitis vinifera as antiatherosclerotic agents | |
| EP1315481A1 (en) | Medicament for treating intestinal diseases | |
| EP0886522B1 (en) | Use of colostrum for the treatment of constipation | |
| CN101057861B (en) | Polycarbophil enteric coated medicinal composition | |
| WO2005074952A1 (en) | Chinese medicine for treatment of irritable bowel sysndrome and the preparation thereof | |
| CA2244094A1 (en) | Use of colostrum for the treatment of constipation | |
| EP0917467B1 (en) | Pharmaceutical formulations containing colostrum and their use | |
| CN116098224A (en) | Pressed candy for regulating uric acid and preparation method thereof | |
| EP3595632B1 (en) | Composition for use in the treatment of endometriosis and symptoms associated with endometriosis | |
| CN101450199A (en) | Medicine composition for treating acute gastroenteritis and preparation method thereof | |
| CN102283861A (en) | Application of magnesium hydrate to pharmacy as well as magnesium hydrate preparation and preparation method thereof | |
| CN107789343A (en) | A kind of medicine for treating antimigraine and preparation method thereof | |
| RU2218930C1 (en) | Biologically active supplement "fitogemorroinie" for complex therapy and prophylaxis of hemorrhoid, chronic constipations and vein varicosity | |
| KR100443653B1 (en) | Foods for the treatment of dysmenorrhea | |
| US20200383926A1 (en) | Enteric coated pharmaceutical composition and use thereof | |
| WO2004084867A1 (en) | The colon-targeted pharmaceutical compositions of gastrointestinal motility drugs and their use | |
| KR100447327B1 (en) | Drugs for the treatment of dysmenorrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |